CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
Sildenafil study groupdrug
Likely dose
Sildenafil study group 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03733470
NCT03733470Phase 4Completed
CompareCT.gov

Pilot Study for Perfusion Heterogeneity: a Mechanistic Image-Based Emphysema Phenotype

Eric A. Hoffman·interventional·Posted Nov 7, 2018·Updated Oct 1, 2019

In Brief

A Phase 4 clinical trial evaluating Sildenafil study group for Emphysema. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEmphysema
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2018
Enrollment StartJun 29, 2011
Primary CompletionJan 13, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.7 years ago

Interventions

Sildenafil study groupdrug

One dose of 20 mg Sildenafil will be given one hour before CT imaging.